The move signals a major expansion milestone for the Swiss laboratory automation company
The bonds, due June 15, 2030, were placed with Swiss investors under the joint lead of UBS and Zürcher Kantonalbank
The company is expected to conduct further studies to confirm the long-term efficacy and safety of Vijoice in both adult and paediatric patients
No approved vaccine or specific treatment currently available for Bundibugyo strain Ebola disease
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
The approval was granted by Agenzia Italiana del Farmaco
Q4FY26 revenue climbs 19% to Rs. 2,290 crore as CDMO sterile injectables, radiopharma and generics businesses drive growth momentum
NGI will deliver full end-to-end workflows using both EpiFinder cNUC and EpiFinder GenomePro
Combined company targets Rs. 2,500–3,000 crore revenue by 2030; new sterile and OSD plants to begin operations by August 2026
Subscribe To Our Newsletter & Stay Updated